The role of leptin in pathophysiology of myeloma cells

Yakhteh

Volumn 12, Issue 3, 2010, Pages 319-328

  Vaghef, Najmeh ^a   Abroun, Saeid ^a   Kaviani, Saeid ^a   Alimoghadam, Kamran ^b   Rostami, Sharbanoo ^a   Sadeghi, Bahare ^a   Saki, Najmedin ^a   Khamisipour, Gholamreza ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Leptin; Multiple myeloma; U266 cell line

Indexed keywords

INTERLEUKIN 6; LEPTIN; LEPTIN RECEPTOR; RECOMBINANT LEPTIN;

ARTICLE; BONE MARROW; CANCER CELL CULTURE; CELL GROWTH; CELL STRAIN; CELL STRAIN RPMI 8866; CELL STRAIN U 266; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MICROENVIRONMENT; MULTIPLE MYELOMA; MYELOMA CELL; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 78650472217     PISSN: 15614921     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Kyle RA. Diagnostic criteria of multiple myeloma. Hematol Oncol Clin North Am. 1992; 6(2): 347-358.
2. Hideshima T, Nergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood. 2004; 104(3): 607-618. (Pubitemid 38970551)
3. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005; 23(26): 6333-6338. (Pubitemid 46218843)
4. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004; 64(4): 1546-1558.
5. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004; 64(4): 1546-1558.
6. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood. 2004; 104: 607-618. (Pubitemid 38970551)
7. Hideshima T, Podar K, Chauhan D, Anderson KC. Cytokines and signal transduction. Best Pract Res Clin Haematol. 2005; 18(4): 509-524.
8. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J , Levitzki A, Savino R, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999; 10: 105-115.
9. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988; 332: 83-85.
10. Chatterjee M, Stuhmer T, Herrmann P, Bommert K, Dorken B, Bargou RC. Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood. 2004; 104: 3712-3721.
11. Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, et al. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood. 2004;103:3175-3184.
12. Hilbert DM, Kopf M, MockBA, Kohler G, Rudikoff S. Interleukin 6 is essential for in vivo development of B lineage neoplasms. J Exp Med. 1995; 182: 243-248.
13. Trikha M, Corringham R, Klein B, Rossi JF. Targeted antiinterleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res. 2003; 9: 4653-4665. (Pubitemid 37323267)
14. Lentzsch S, Chatterjee M, Gries M, Bommert K, Gollasch H, Dörken B, et al. PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukaemia. 2004; 18:1883-1890.
15. Tai YT, Podar K, Catley L, Tseng YH, Akiyama M, Shringarpure R, et al. Insulin-like growth factor-1 induces adhesion and phosphatidylinositol 3-kinase/AKT signaling. Cancer Res. 2003; 63: 5850-5858.
16. Klein B, Tarte K, Jourdan M, Mathouk K, Moreaux J, Jourdan E, et al. Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol. 2003; 78: 106-113. (Pubitemid 37021949)
17. Bommert K, Bargou RC, Stuhmer T. Signaling and survival pathways in multiple myeloma. Eur J Cancer. 2006;42:1574-1580. (Pubitemid 44118772)
18. Kim KH, Kim YJ, Lee S, Oh SW, Lee K, Park Y, Kim HJ, Kwak H. Evaluation of plasma leptin levels & BMI as predictor of postpartum weight retention. India J Med Res. 2008; 128(5): 595-600.
19. Bates SH, Myers MG Jr. The role of leptin receptor signaling in Feeding and neuroendocrine function. Trends Endocrinol Metab. 2003; 14(10): 447-452.
20. Mantzoros CS. Role of Leptin in Reproduction. Ann N Y Acad Sei. 2000; 900:174-83.
21. Bouloumie A, Drexler HC, Lafontan M, Busse R. Leptin, the Product of Ob Gene, promotes angiogenesis. Circ Res 1998; 83:1059-1066. (Pubitemid 28520935)
22. Lago R, Gómez R, Lago F, Gómez-Reino J, Gualillo O.Leptin beyond body weight regulation-current concepts concerning its role in immune function and inflammation. Cell Immunol. 2008; 252(1-2): 139-45.
23. Lam QL, Lu L. Role of leptin in immunity. Cell Mol Immunol. 2007; 4(1): 1-13.
24. La Cava A, Matarese G. The Weight of Leptin in Immunity. Nat Rev Immunol 2004; 4: 371-379.
25. Gainsford T, Willson TA, Metcalf D, Handman E, McFarlane C, Ng A, et al. Leptin can induce proliferation, differentiation, and functional activation of hematopoietic cells. Proc Natl Acad Sci USA. 1996; 93(25): 14564-14568.
26. Gainsford T, Alexander WS: A Role for Leptin in hemopoieses? Mol Biotechnol. 1999; 11: 149-158.
27. Bennett BD, Solar GP, Yuan JQ, Mathias J, Thomas GR, Matthews W. A role for leptin and its cognate receptor in hematopoiesis Curr Biol. 1996; 6(9): 1170-1180.
28. Murad A, Nath AK, Cha ST, Demir E, Flores-Riveros J, Sierra-Honigmann MR.Leptin is an autocrine/ paracrine regulator of wound healing. FASEB J. 2003; 17(13): 1895-1897.
29. Astudillo P, Rios S, Pastenes L, Pino AM, Rodriguez JP. Increased adipogenesis of osteoporotic human-mesenchymal stem cells (MSCs) characterizes by impaired leptin action. J Cell Biochem. 2008; 103: 1054-1065.
30. Karsenty G. Convergence between bone and energy homeostases: Leptin regulation of bone mass. Cell Metab. 2006; 4: 341-348. (Pubitemid 44645074)
31. Heep H, Wedemeyer C, Wegner A, Hofmeister S, von Knoch M. Differences in trabecular bone of leptindeficient ob/ob mice in response to biomechanical loading. Int J Biol Sei. 2008; 4(3):169-175. (Pubitemid 351872044)
32. Kim GS, Hong JS, Kim SW, Koh JM, An CS, Choi JY, et al. Leptin induces apoptosis via ERK/cPLA2/cytochrome c pathway in human bone marrow stromal cells. J Biol Chem. 2003; 278(24): 21920-21929.
33. Ren J. Leptin and hyperleptinemia-from friend to foe for cardiovascular function. J Endocrinol. 2004; 181: 1-10. (Pubitemid 38584659)
34. Samara A, Marie B, Pfister M, Visvikis-Siest S. Leptin expression in Peripheral Blood Mononuclear Cells (PBMCs) is related with blood pressure variability. Clin Chim Acta. 2008; 395(1-2): 47-50.
35. Wex H, Ponelis E, Wex T, Dressendörfer R, Mittler U, Vorwerk P. Plasma leptin and leptin receptor expression in childhood acute lymphoblastic leukemia. Int J Hematol. 2002; 76(5): 446-452.
36. Nakao T, Hino M, Yamane T, Nishizawa Y, Morii H, Tatsumi N: Expression of the leptin receptor in human Ieukaemic blast cells. Br J Haematol. 1998; 102: 740-745.
37. Dalamaga M, Karmaniolas K, Panagiotou A, Hsi A, Chamberland J, Dimas C, et al. Low circulating adiponectin and resistin, but not leptin, levels are associated multiple myeloma risk: a case control study. Cancer Causes Control. 2009; 20(2): 193-199.
38. Pamuk GE, Demir M, Harmandar F, Yesil Y, Turgut B, Vural O. Leptin and resistin leveles in serum of patients With hematologic malignancies: correlation with clinical characteristics. Exp Oncol. 2006; 28(3): 241-244.
39. Reseland JE, Reppe S, Olstad OK, Hjorth-Hansen H, Brenne AT, Syversen U, et al. Abnormal adipokine levels and leptin-induced changes in gene expression profiles in multiple myeloma. Eur J Haematol. 2009; 83: 460-470.
40. Schwab G, Siegall CB, Aarden LA, Neckers LM, Nordan RP. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood. 1991; 77(3): 587-593.
41. Tabe Y, Konopleva M, Munsell MF, Marini FC, Zompetta C, McQueen T, et al. PML-RAR {alpha} is associated with leptin-Receptore induction: the role of mesenchymal stem cell-drived adipoctes in APL cell survival. Blood. 2004; 103: 1815-1822.
42. Larsson SC, Wolk A. Body mass index and risk of multiple myeloma: A meta- analysis. Int. J Cancer. 2007; 121:2512-2516.
43. Fruhbeck G. Intracellular signaling pathways activated by by leptin. Biochem J. 2006; 393(Pt 1): 7-20.